Gilead Sciences, Inc.
Explore Gilead Sciences, Inc.
Core profile pages, annual revenue records, and related research hubs for this company.
CorpDigest
Gilead Sciences, Inc.
Explore Gilead Sciences, Inc.
Core profile pages, annual revenue records, and related research hubs for this company.
Annual Revenue
FY2024 Revenue
$28.5B
▲ 5.2% vs FY2023 ($27.1B)
Net Income: $6.6B
Source: Annual report / company filing
Gilead Sciences, Inc. reported $28.5B in revenue for fiscal year 2024. This represents a growth of 5.2% compared to the 2023 figure of $27.1B. In 2025, revenue increased to $29.4B.
Product sales rose 5.2% from 2023 as Biktarvy's $13.8 billion HIV lead and scaling Trodelvy and Yescarta oncology sales offset the steep decline of the COVID antiviral Veklury.
| Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $29.4B | — | +3.3% |
| FY2024 | $28.5B | $6.6B | +5.2% |
| FY2023 | $27.1B | — | -1.5% |
| FY2022 | $27.5B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.